Research ExplorerPublicationsDaratumumab-based regimens are highly effective and well tol...

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Standard

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. / Mateos, Maria-Victoria; Spencer, Andrew; Nooka, Ajay K; Pour, Ludek; Weisel, Katja; Cavo, Michele; Laubach, Jacob P; Cook, Gordon; Iida, Shinsuke; Benboubker, Lotfi; Usmani, Saad Z; Yoon, Sung-Soo; Bahlis, Nizar J; Chiu, Christopher; Ukropec, Jon; Schecter, Jordan M; Qin, Xiang; O' Rourke, Lisa; Dimopoulos, Meletios A.

In: HAEMATOLOGICA, Vol. 105, No. 2, 2020, p. 468-477.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mateos, M-V, Spencer, A, Nooka, AK, Pour, L, Weisel, K, Cavo, M, Laubach, JP, Cook, G, Iida, S, Benboubker, L, Usmani, SZ, Yoon, S-S, Bahlis, NJ, Chiu, C, Ukropec, J, Schecter, JM, Qin, X, O' Rourke, L & Dimopoulos, MA 2020, 'Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies', HAEMATOLOGICA, vol. 105, no. 2, pp. 468-477. https://doi.org/10.3324/haematol.2019.217448

APA

Mateos, M-V., Spencer, A., Nooka, A. K., Pour, L., Weisel, K., Cavo, M., Laubach, J. P., Cook, G., Iida, S., Benboubker, L., Usmani, S. Z., Yoon, S-S., Bahlis, N. J., Chiu, C., Ukropec, J., Schecter, J. M., Qin, X., O' Rourke, L., & Dimopoulos, M. A. (2020). Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. HAEMATOLOGICA, 105(2), 468-477. https://doi.org/10.3324/haematol.2019.217448

Vancouver

Mateos M-V, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. HAEMATOLOGICA. 2020;105(2):468-477. https://doi.org/10.3324/haematol.2019.217448

Bibtex

@article{7489673eb5dc4b71941ce4c1e630381d,
title = "Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies",
abstract = "The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age groups of 65 to 74 years and ≥75 years. Patients received ≥1 prior line of therapy. In POLLUX, patients received lenalidomide/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-2; every two weeks, cycles 3-6; monthly until progression). In CASTOR, patients received eight cycles of bortezomib/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-3; every three weeks, cycles 4-8; monthly until progression). Patients aged >75 years received dexamethasone 20 mg weekly. For patients aged ≥75 years in POLLUX (median follow-up: 25.4 months), daratumumab/lenalido-mide/dexamethasone prolonged progression-free survival versus lenalido-mide/dexamethasone (median: 28.9 versus 11.4 months; hazard ratio, 0.27; 95% confidence interval, 0.10-0.69; P=0.0042) and increased overall response rate (93.1% versus 76.5%; P=0.0740). Neutropenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 44.8%; control: 31.4%). Infusion-related reactions occurred in 12 (41.4%) patients. For patients aged ≥75 years in CASTOR (median follow-up: 19.4 months), daratumumab/bortezomib/dexamethasone prolonged progression-free survival versus bortezomib/dexamethasone (median: 17.9 versus 8.1 months; hazard ratio, 0.26; 95% confidence interval, 0.10-0.65; P=0.0022) and increased overall response rate (95.0% versus 78.8%; P=0.1134). Thrombocytopenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 45.0%; control: 37.1%). Infusion-related reactions occurred in 13 (65.0%) patients. Similar findings were reported for patients aged 65 to 74 years in both studies. Taken together, this subgroup analysis of efficacy and safety of daratumumab was largely consistent with the overall populations.",
author = "Maria-Victoria Mateos and Andrew Spencer and Nooka, {Ajay K} and Ludek Pour and Katja Weisel and Michele Cavo and Laubach, {Jacob P} and Gordon Cook and Shinsuke Iida and Lotfi Benboubker and Usmani, {Saad Z} and Sung-Soo Yoon and Bahlis, {Nizar J} and Christopher Chiu and Jon Ukropec and Schecter, {Jordan M} and Xiang Qin and {O' Rourke}, Lisa and Dimopoulos, {Meletios A}",
note = "Copyright{\textcopyright} 2020 Ferrata Storti Foundation.",
year = "2020",
doi = "10.3324/haematol.2019.217448",
language = "English",
volume = "105",
pages = "468--477",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

RIS

TY - JOUR

T1 - Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

AU - Mateos, Maria-Victoria

AU - Spencer, Andrew

AU - Nooka, Ajay K

AU - Pour, Ludek

AU - Weisel, Katja

AU - Cavo, Michele

AU - Laubach, Jacob P

AU - Cook, Gordon

AU - Iida, Shinsuke

AU - Benboubker, Lotfi

AU - Usmani, Saad Z

AU - Yoon, Sung-Soo

AU - Bahlis, Nizar J

AU - Chiu, Christopher

AU - Ukropec, Jon

AU - Schecter, Jordan M

AU - Qin, Xiang

AU - O' Rourke, Lisa

AU - Dimopoulos, Meletios A

N1 - Copyright© 2020 Ferrata Storti Foundation.

PY - 2020

Y1 - 2020

N2 - The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age groups of 65 to 74 years and ≥75 years. Patients received ≥1 prior line of therapy. In POLLUX, patients received lenalidomide/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-2; every two weeks, cycles 3-6; monthly until progression). In CASTOR, patients received eight cycles of bortezomib/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-3; every three weeks, cycles 4-8; monthly until progression). Patients aged >75 years received dexamethasone 20 mg weekly. For patients aged ≥75 years in POLLUX (median follow-up: 25.4 months), daratumumab/lenalido-mide/dexamethasone prolonged progression-free survival versus lenalido-mide/dexamethasone (median: 28.9 versus 11.4 months; hazard ratio, 0.27; 95% confidence interval, 0.10-0.69; P=0.0042) and increased overall response rate (93.1% versus 76.5%; P=0.0740). Neutropenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 44.8%; control: 31.4%). Infusion-related reactions occurred in 12 (41.4%) patients. For patients aged ≥75 years in CASTOR (median follow-up: 19.4 months), daratumumab/bortezomib/dexamethasone prolonged progression-free survival versus bortezomib/dexamethasone (median: 17.9 versus 8.1 months; hazard ratio, 0.26; 95% confidence interval, 0.10-0.65; P=0.0022) and increased overall response rate (95.0% versus 78.8%; P=0.1134). Thrombocytopenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 45.0%; control: 37.1%). Infusion-related reactions occurred in 13 (65.0%) patients. Similar findings were reported for patients aged 65 to 74 years in both studies. Taken together, this subgroup analysis of efficacy and safety of daratumumab was largely consistent with the overall populations.

AB - The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age groups of 65 to 74 years and ≥75 years. Patients received ≥1 prior line of therapy. In POLLUX, patients received lenalidomide/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-2; every two weeks, cycles 3-6; monthly until progression). In CASTOR, patients received eight cycles of bortezomib/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-3; every three weeks, cycles 4-8; monthly until progression). Patients aged >75 years received dexamethasone 20 mg weekly. For patients aged ≥75 years in POLLUX (median follow-up: 25.4 months), daratumumab/lenalido-mide/dexamethasone prolonged progression-free survival versus lenalido-mide/dexamethasone (median: 28.9 versus 11.4 months; hazard ratio, 0.27; 95% confidence interval, 0.10-0.69; P=0.0042) and increased overall response rate (93.1% versus 76.5%; P=0.0740). Neutropenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 44.8%; control: 31.4%). Infusion-related reactions occurred in 12 (41.4%) patients. For patients aged ≥75 years in CASTOR (median follow-up: 19.4 months), daratumumab/bortezomib/dexamethasone prolonged progression-free survival versus bortezomib/dexamethasone (median: 17.9 versus 8.1 months; hazard ratio, 0.26; 95% confidence interval, 0.10-0.65; P=0.0022) and increased overall response rate (95.0% versus 78.8%; P=0.1134). Thrombocytopenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 45.0%; control: 37.1%). Infusion-related reactions occurred in 13 (65.0%) patients. Similar findings were reported for patients aged 65 to 74 years in both studies. Taken together, this subgroup analysis of efficacy and safety of daratumumab was largely consistent with the overall populations.

U2 - 10.3324/haematol.2019.217448

DO - 10.3324/haematol.2019.217448

M3 - SCORING: Journal article

C2 - 31221782

VL - 105

SP - 468

EP - 477

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 2

ER -